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Background: Primary hyperoxaluria type 1 is a rare autosomal recessive disease of glyoxylate metabolism caused by a
defect in the liver-specific peroxisomal enzyme alanine:glyoxylate aminotransferase (AGT) that leads to hyperoxaluria,
recurrent urolithiasis, and nephrocalcinosis.
Methods: Two unrelated patients with recurrent urolithiasis, along with members of their families, exhibited mutations
in the AGXT gene by PCR direct sequencing.
Results: Two heterozygous mutations that predict truncated proteins, p.S81X and p.S275delinsRAfs, were identified in
one patient. The p.S81X mutation is novel. Two heterozygous missense mutations, p.M1T and p.I202N, were detected
in another patient but were not identified in her sibling. These four mutations were confirmed to be of paternal and
maternal origin.
Conclusions: These are the first cases of primary hyperoxaluria type 1 to be diagnosed by clinical manifestations and
AGXT gene mutations in mainland China. The novel p.S81X and p.I202N mutations detected in our study extend the
spectrum of known AGXT gene mutations.
Keywords: AGXT gene, Chinese children, Mutational analysis, Novel mutation, Primary hyperoxaluria type 1Background
Primary hyperoxaluria type 1 (PH1; MIM# 259900) is an
autosomal recessive disorder of glyoxylate metabolism,
leading to the overproduction of endogenous oxalate;
patients present with urolithiasis and/or nephrocalcinosis
[1,2]. The disease is caused by mutations in the AGXT
gene (MIM#604285), which encodes the hepatic peroxi-
somal enzyme alanine:glyoxylate aminotransferase (AGT;
EC 2.6.1.44), a pyridoxal 5′-phosphate (PLP)-dependent
enzyme that catalyses the transamination of glyoxylate to
glycine [3,4]. Approximately 50% of patients who present
with PH1 in childhood will have end-stage renal failure
by the age of 15 years. PH1 is a condition that leads to
systemic oxalosis with oxalate precipitation in the eye,
heart, and bones and that results in significant morbidity
and mortality [5,6]. The incidence of PH1 is estimated at 1
in 120,000 live births with prevalence ranging from 1.05/
106 to 2.9/106 in France, Switzerland, and the Netherlands* Correspondence: hxu@shmu.edu.cn; ay.fudan@gmail.com
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unless otherwise stated.[5,7-9]. Excessive oxalate excretion is an indicator of
this disease; however, the test is not specific for PH1
and may have misleading results because oxalate excretion
may be reduced during renal failure [2,10,11]. Thus, more
sophisticated tests, including genetic analysis and/or
enzymology, are required for diagnosis [12-14]. Although
a few sporadic cases of PH1 have been reported in
mainland China, mutational analysis of AGXT was not
performed in these cases. We identified 2 unrelated cases
of PH1 in mainland China. We analysed the clinical
features, detected AGXT mutations in their families,
and compared our cases with other ethnic or regional
patients previously reported by other authors. We hope
that the presentation of rare cases will contribute to
understanding the spectrum of the disease by aiding its
clinical identification and pathogenetic understanding.Methods
Patients
PH1 was diagnosed in two patients from two unrelated
Chinese families. Patient 1, a 10-year-old girl, presented
with gross haematuria at the age of 3. She went to herhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://www.biomedcentral.com/1471-2369/15/92local hospital, and a renal ultrasound showed several small
stones in the kidneys and no hydronephrosis. Urologists
at the local hospital administered conservative treatment
(i.e., high fluid intake), and her haematuria gradually
disappeared. The patient presented with gross haema-
turia again at the age of 5, this time with abdominal
pain. A renal ultrasound displayed several stones in the
kidneys, a stone (6 mm × 9 mm) in the right ureter, and
right hydronephrosis. An abdominal plain film X-ray
also revealed multiple urolithiasis (Figure 1a). Urologists
at the local hospital administered extracorporeal shock
wave lithotripsy (ESWL). After ESWL, the patient excreted
several stones in her urine, and her gross haematuria and
back pain resolved. The patient developed right back pain
again at age 10. A renal ultrasound indicated multiple
urolithiasis, a stone (5 mm × 9 mm) in the right ureter,
and right hydronephrosis. Renal function tests suggested
elevated levels of both plasma creatinine (185 μmol/L)
and blood urea nitrogen (BUN, 11.10 mmol/L). Urologists
at the local hospital again administered ESWL. After
ESWL, her back pain was remissive, but her renal function
remained abnormal. Therefore, the patient was admitted
to our centre (the Centre of Nephrology and Urology,
Children’s Hospital of Fudan University) for evaluation.
Her parents had no consanguinity, and there was no
family history of renal disease.
On admission, a physical examination showed normal
parameters. Her height was between the 25th and
50th percentile, and her body weight was in the 50thFigure 1 Radiographic findings in patient 1 (a-e) and patient 2 (f-i). A
(volume rendering), d: MIP (maximum intensity projection), e: CT (axial ima
(axial image).percentile. Laboratory tests indicated normal haemoglo-
bin (11.9 g/100 ml) and renal insufficiency (filtration
rate < 45 ml/min/1.73 m2, creatinine level 195 μmol/L,
and BUN 13.20 mmol/L). Blood gases revealed mild
metabolic acidosis (pH 7.28, BE 3.5 mmol/L), and con-
stituent analysis suggested that the stones were composed
of calcium oxalate monohydrate (>95%). An abdominal
computed tomography (CT) scan, CT urography, and
three-dimensional image of CT urography all showed
multiple urolithiasis (Figure 1b,c,d, and e). A CT urog-
raphy and three-dimensional image of CT urography also
revealed right hydronephrosis (Figure 1c and d). Based
on the clinical data, PH1 and chronic kidney disease
stage 3 (CKD 3) were diagnosed. The patient received
conservative treatment, including a high fluid intake,
oral potassium citrate, and vitamin B6 (pyridoxine). The
patient progressed to CKD 5 within 7 months, after which
she received haemodialysis three times a week. The
adequacy of haemodialysis was good (Kt/v 1.49, urea
clearance 70%). The levels of calcium and phosphorus
in the blood were normal, and parathyroid hormone
levels were between 280 to 320 pg/L.
The parents had been clinically evaluated as normal at
the affiliated Obstetrics and Gynaecology Hospital of
Fudan University. The parents were experiencing their
second pregnancy (20 weeks gestation) and were referred
to our centre for prenatal genetic diagnosis.
Patient 2, a 7-year-old girl, presented with gross haema-
turia and abdominal pain at the age of 5. She went to herrrows indicate stones. a: abdominal X-ray, b: CT (coronal image), c: VR
ge), f: ultrasound, g: VR (volume rendering), h: CT (coronal image), i: CT
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Urologists at the local hospital administered conservative
treatment, including a high fluid intake and herbal medi-
cine. After treatment, the patient excreted several stones
in the urine, and her symptoms disappeared. The patient
developed gross haematuria and abdominal pain again at
the age of 6, and a renal ultrasound showed urolithiasis
and right hydronephrosis (Figure 1f). Urologists at the
local hospital continued to administer conservative treat-
ment because the stones in the kidneys were small and
stones were periodically excreted in her urine. At 7 years of
age, the patient was referred to our centre for evaluation.
Her parents had no consanguinity, and there was no family
history of renal disease.
On admission, a physical examination indicated normal
parameters. Her height was between the 75th and 90th
percentile, and her body weight was in the 75th percentile.
Laboratory tests revealed haematuria (8 RBCs/HPF),
normal haemoglobin (12.1 g/100 ml), and normal renal
function (filtration rate <90 ml/min/1.73 m2, creatinine
level 49.0 mmol/L, and BUN 3.7 mmol/L). The blood
gases were normal (pH 7.35, BE 1 mmol/L), and the
parathyroid hormone level was normal. Constituent
analysis also suggested that the stones were made of
calcium oxalate monohydrate (>95%). An abdominal CT
scan indicated multiple urolithiasis (Figure 1g,h, and i).
Based on the clinical data, the patient was diagnosed
with PH1. The patient received conservative treatment,
such as a high fluid intake, oral potassium citrate, and
vitamin B6 (pyridoxine). The patient's condition is cur-
rently being followed in our centre, and her renal function
is normal.
The medical histories of the two families were also
investigated. Informed consent was obtained from the
parents. Ethical committee approval was obtained from
the Ethical Committee of Children’s Hospital of Fudan
University.
Mutation analysis of the AGXT gene
Genomic DNA was extracted from the members of both
families and purified from peripheral leukocytes in whole-
blood samples and cast-off cells in amniotic fluid using
a DNA isolation kit. All AGXT exons were amplified by
polymerase chain reaction (PCR). The AGXT primers
were designed on the basis of previously published
information regarding intron-exon boundaries [15,16].
The PCR products were purified with a QIAquick PCR
Purification Kit (Qiagen, Hilden, Germany). The purified
products were cycle-sequenced with Big Dye terminators
(Applied Biosystems, Foster City, CA, USA), and the cycle
sequence products were analysed with an automated se-
quencer (ABI Prism 310 Genetic Analyser). Novel AGXT
mutations were investigated in 100 healthy controls by
direct sequencing.In silico prediction of amino-acid substitution
Nonsynonymous sequence variants of genes were analysed
with the PolyPhen-2 software [17] and SIFT algorithm [18]
to predict the impact of the amino-acid substitution.
PolyPhen-2 calculates a Naive Bayes posterior probability
that any mutation is damaging by the representation of a
score ranging from 0 to 1 and predicts qualitative damage
based on the model’s false positive rate (benign, possibly
damaging, or probably damaging). The SIFT prediction is
based on the degree of conservation of amino-acid resi-
dues in sequence alignments derived from closely related
sequences, which also provides a prediction of qualitative
damage (tolerated or damaging).
Web resources
The following GenBank sequences (http://www.ncbi.nlm.
nih.gov/Genbank/) served as reference files: NT_005416
for AGXT genomic nucleotide position and NM_000030.2
for AGXT cDNA position. Uni-ProtKB (http://www.uniprot.
org/uniprot/P21549, ID: P21549) and Ensembl Genome
Browser (http://www.ensembl.org, ID: ENST00000307503)
were used to determine the AGXT amino-acid position,
and Clustal W (http://www.ebi.ac.uk/clustalw/) was used
for multiple sequence alignment.
Results
Clinical features
Two girls presented with recurrent and multiple urolith-
iasis and were diagnosed with PH1. Patient 1 progressed
to end-stage renal disease at the age of 10.6 years. The
renal function of patient 2 is currently normal. Renal
ultrasounds and urinary analyses were both normal in
other members of the families. The clinical features are
summarised in Table 1.
Mutational analysis of the AGXT gene
Family 1
Two heterozygous mutations, p.S81X (c.242C >A) in exon
2 and p.S275delinsRAfs (c.823_824dupAG) in exon 7,
were identified in patient 1, and these mutations were
inherited from each parent. The p.S275delinsRAfs muta-
tion has been previously reported as a disease-causing
mutation. An additional nonsense mutation of p.Ser81X
that creates a truncated AGT is novel and was not iden-
tified in 100 healthy controls; this mutation is hypothe-
sised to be pathogenic. A recessive genetic model of the
compound heterozygous mutations of AGXT in patient
1 indicated the cause of PH1. After the mutations were
confirmed in family 1, AGXT mutational analysis was then
performed for the foetus using an amniotic fluid sample
for prenatal genetic diagnosis. This analysis revealed no
mutations in the exons, indicating that the nonsense p.
S81X mutation and the frameshift p.S275delinsRAfs
mutation (Figure 2a) were not inherited.
Table 1 Clinical features and AGXT mutations in two patients with PH1














1 Female 3 10.6 Recurrent urolithiasis No Multiple urolithiasis p.S81X Mother Het
p.S275delinsRAfs Father Het
2 Female 5 - Recurrent urolithiasis No Multiple urolithiasis p.M1T Father Het
p.I202N Mother Het
-:no progression to ESRD.
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Two heterozygous missense mutations, p.M1T (c.2 T > C)
in exon 1 and p.I202N (c.605 T > A ) in exon 6, were
detected in patient 2 (Figure 2b), and these mutations
were inherited from each parent. The p.M1T mutation has
been previously reported, whereas the p.I202N mutation
is novel and was not identified in 100 healthy controls.
PolyPhen-2 predicts the pathogenicity of p.I202N to be
“Probably Damaging” with a score of 0.968 (sensitivity:
0.77; specificity: 0.95) (Figure 2c); SIFT software predicted
this mutation to be harmful, with a score of 0.03. In
addition, multiple sequence alignments revealed that the
p.I202N mutation occurs in a residue that is highly evo-
lutionarily conserved among humans, Norway rats, Mus
musculus, Danio rerio and chimpanzees (Figure 2d).
Discussion
PH1 is a severe autosomal recessive inherited disorder of
glyoxylate metabolism caused by mutations in the AGXT
gene on chromosome 2q37.3 that encodes the liver-specificFigure 2 AGXT gene mutational analysis. Two mutations, p.S81X and p.S
patient 2 (b). PolyPhen-2 predicted the p.I202N mutation to be a “damagin
Alignment of the mutated p.I202N AGT protein with different species show
Arrows indicate the mutation sites. P1: patient 1, P2: patient 2, F: father, M:PLP-dependent enzyme AGT [4]. More than 150 different
pathogenic mutations, including nonsense, frameshift, and
missense mutations, in the AGXT gene that cause PH1 have
been identified to date (http://www.hgmd.cf.ac.uk/ac/gene.
php?gene=AGXT). While nonsense and frameshifts are
null mutations that lead to the complete loss of the gene
product, the most common type of AGXT mutations are
single amino-acid substitutions that lead to the synthesis
of an aberrant gene product [6]. These mutations are
found throughout the entire gene and cause a wide
spectrum of clinical severity.
The four most common AGXT mutations in PH1 in
European and North American patients are p.G170R, p.
F152I, p.I244T and c.33−34insC [19,20]. The p.S205P
mutation is a PH1-specific mutation in Japanese patients
[21]. In the present study, mutational analysis of the
AGXT gene in two Chinese families with PH1 revealed
two patients who had compound heterozygous mutations.
One patient had p.S81X and p.S275delinsRAfs mutations,
and the other had p.M1T and p.I202N mutations. Theseer275delinsRAfs, in patient 1 (a). Two mutations, p.M1T and p.I202N, in
g mutation” with a score of 0.968 (sensitivity: 0.77; specificity: 0.95) (c).
s the complete conservation of the amino acid in grey (d).
mother, F1: foetus.
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AGXT mutations in European and North American
patients, which are also different from the PH1-specific
mutation (p.S205P) in Japanese patients. The p.S275delins-
RAfs and p.M1T mutations have been previously reported
[22,23]. The p.M1T mutation was first reported in another
Chinese study from Hong Kong in 2004 [23]. This muta-
tion has not been reported in other populations to date.
The other two mutations, p.S81X and p.I202N, are novel.
The p.S81X mutation is a nonsense mutation that leads
to a truncated AGT, and this mutation was speculated
to be a pathogenic mutation. p.I202N is another missense
mutation and is located on exon 6. Exon 6 spans the PLP
co-factor binding site consensus sequence (amino acids
201–221) common to aminotransferases and is critical to
the catalytic site [24]. Crystallisation studies confirmed
that the lysine at codon 209 in exon 6 is the actual site of
the Schiff base with PLP [25]. The alignment of AGT pro-
teins from several species revealed that the isoleucine at
codon 202 is 100% conserved across all analysed species
(Figure 2d) and constitute one of the amino acids in
the sequence of a highly conserved region of AGT pro-
tein. Several clinical reports identified nine mutations
also located in this highly conserved sequence motif
[6,21,26-29]. Given the predictions of the in silico
PolyPhen-2 and SIFT analyses and the fact that the mu-
tation was not identified in 100 healthy controls, the
missense p.I202N mutation identified in patient 1 in this
highly conserved sequence motif is hypothesised to be a
damaging mutation. Therefore, the two novel mutations, p.
S81X and p.I202N, were not identified in 100 healthy con-
trols and are considered to be disease-causing mutations.
AGXT gene mutations result in deficiency and/or
mistargeting of hepatic AGT, which leads to metabolic
overproduction of oxalate and glycolate. The excess
oxalate is excreted in the urine but is of low solubility
and precipitates as a calcium salt, resulting in urolith-
iasis, nephrocalcinosis, and progressive renal insufficiency
[11,30]. Both patients in this study presented with haema-
turia, back pain, and recurrent urolithiasis. Radiographic
screening revealed multiple urolithiasis in both patients.
Stone analysis revealed the main component of the stones
to be calcium oxalate monohydrate (>95%). The patient
with p.S81X and p.S275delinsRAfs mutations, presenting
at the age of 3, did not respond to treatment with pyridox-
ine and progressed rapidly to end-stage renal disease
(ESRD) at the age of 10.6. This patient displayed serious
clinical features given that she had compound truncation
mutations, which led to hepatic AGT deficiency. The
patient with the p.M1T and p.I202N missense mutations
presented at the age of 5 and received conservative
treatment, including a high fluid intake, oral potassium
citrate, and oral pyridoxine. Currently, her renal function is
normal. PH1 may present at any age [4]. The presentationvaries from infantile nephrocalcinosis and failure to thrive
as a result of renal impairment to recurrent or occasional
stone formation [30]. Patients should undergo metabolic
screening for PH1 at the presentation of a first kidney stone
(in a child), in recurrent or familial stone disease (at
any age), or if nephrocalcinosis is detected [10,31]. Stone
analysis may reveal characteristic morphology and whether
the stone contains > 95% calcium oxalate monohydrate,
which often presents with a particular morphology [32].
PH1 should be considered in any patient with renal failure
of unknown cause, particularly in the presence of nephro-
calcinosis or severe stone burden, because PH1 accounts
for 1 to 2% of cases of paediatric ESRD according to
registries from Europe, the United States, and Japan [33].
Radiographic screening of the kidneys may elucidate
stones and/or medullary or diffuse nephrocalcinosis [30].
Although hepatic biopsy is the gold standard for PH1
diagnosis, it is invasive, and facilities for the estimation
of enzyme activity are not available in many countries,
especially developing countries. Hence, molecular diagno-
sis using direct sequencing of the whole AGXT gene is
recommended. Therefore, the gold standard method of
diagnosis—liver-biopsy-proven enzyme deficiency or
enzyme mislocalisation—is now exclusively performed
in patients for whom clinical suspicion is still evident
but mutation analysis did not result in a precise diag-
nosis [2].
This is the first mutational analysis of PH1 performed in
mainland China. Because facilities for enzyme estimation
of liver biopsies are not available in most centres, there is
a need to define clinical features and family histories of
consanguinity. We believe that the findings of nephrocal-
cinosis, recurrent urolithiasis, and progressive renal failure
in patients with severe stone burden are sufficient to
clinically diagnose PH1. Detection of mutations in the
AGXT gene may confirm the diagnosis of PH1.Conclusions
These are the first cases of primary hyperoxaluria type 1
to be diagnosed by clinical manifestations and AGXT
gene mutations in mainland China. The novel p.S81X
and p.I202N mutations detected in our study extend the
spectrum of known AGXT gene mutations. The p.M1T
mutation may be specific to Chinese patients.Competing interests
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